Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study.

Miller PE, Rambachan A, Hubbard RJ, Li J, Meyer AE, Stephens P, Mounts AW, Rolfes MA, Penn CR.

PLoS One. 2012;7(9):e43491. doi: 10.1371/journal.pone.0043491. Epub 2012 Sep 11.

2.

Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study.

Miller PE, Rambachan A, Hubbard RJ, Li J, Meyer AE, Stephens P, Mounts AW, Rolfes MA, Penn CR.

Influenza Other Respir Viruses. 2013 Sep;7 Suppl 2:82-6. doi: 10.1111/irv.12092. Review.

3.

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikić D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodríguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skręt-Magierło J, Stephan F, Talarek E, Tang JW, To KK, Torres A, Törün SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS.

Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. Epub 2014 Mar 19. Review.

PMID:
24815805
4.

Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.

Sugaya N, Sakai-Tagawa Y, Bamba M, Yasuhara R, Yamazaki M, Kawakami C, Yamaguchi Y, Ide Y, Ichikawa M, Mitamura K, Kawaoka Y.

Antivir Ther. 2015;20(1):49-55. doi: 10.3851/IMP2798. Epub 2014 May 16.

PMID:
24832015
5.

Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.

Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R.

Infect Disord Drug Targets. 2013 Feb;13(1):34-45. Review.

PMID:
23675925
6.

Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.

Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, Yamauchi S, Hirotsu N, Nishimura M, Iwaki N, Kashiwagi S.

J Infect Chemother. 2011 Jun;17(3):375-81. doi: 10.1007/s10156-010-0179-9. Epub 2010 Dec 1.

PMID:
21120678
7.

Systematic review of influenza resistance to the neuraminidase inhibitors.

Thorlund K, Awad T, Boivin G, Thabane L.

BMC Infect Dis. 2011 May 19;11:134. doi: 10.1186/1471-2334-11-134. Review.

8.

Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.

Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H.

J Infect Chemother. 2012 Dec;18(6):858-64. doi: 10.1007/s10156-012-0428-1. Epub 2012 May 29.

PMID:
22644080
9.

Neuraminidase inhibitors for critically ill children with influenza.

Louie JK, Yang S, Samuel MC, Uyeki TM, Schechter R.

Pediatrics. 2013 Dec;132(6):e1539-45. doi: 10.1542/peds.2013-2149. Epub 2013 Nov 25.

10.

Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.

Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Iwaki N, Kashiwagi S.

Clin Infect Dis. 2009 Dec 15;49(12):1828-35. doi: 10.1086/648424.

PMID:
19911968
11.

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.

Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H.

Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.

PMID:
23791870
12.

Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

Wolkewitz M, Schumacher M.

Lancet Respir Med. 2014 Jul;2(7):e8-9. doi: 10.1016/S2213-2600(14)70115-8. Epub 2014 Jun 16. No abstract available.

PMID:
24948434
13.

Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

Leonardi-Bee J, Venkatesan S, Muthuri SG, Nguyen-Van-Tam JS, Myles PR; PRIDE research consortium.

Lancet Respir Med. 2014 Jul;2(7):e10-2. doi: 10.1016/S2213-2600(14)70137-7. Epub 2014 Jun 16. No abstract available.

PMID:
24948433
14.

Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

Jones M, Del Mar C, Hama R.

Lancet Respir Med. 2014 Jul;2(7):e9-e10. doi: 10.1016/S2213-2600(14)70126-2. Epub 2014 Jun 16. No abstract available.

PMID:
24948431
15.

Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

Antes G, Meerpohl JJ.

Lancet Respir Med. 2014 Jul;2(7):e10. doi: 10.1016/S2213-2600(14)70127-4. Epub 2014 Jun 16. No abstract available.

PMID:
24948429
16.

Effectiveness of neuraminidase inhibitors for severe influenza.

Fry AM.

Lancet Respir Med. 2014 May;2(5):346-8. doi: 10.1016/S2213-2600(14)70068-2. Epub 2014 Mar 19. No abstract available.

PMID:
24815800
17.

Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.

Kawai N, Ikematsu H, Kawashima T, Maeda T, Ukai H, Hirotsu N, Iwaki N, Kashiwagi S.

Influenza Other Respir Viruses. 2013 May;7(3):448-55. doi: 10.1111/j.1750-2659.2012.00421.x. Epub 2012 Aug 16.

18.

The use of antiviral agents for the management of severe influenza.

Smith JR, Ariano RE, Toovey S.

Crit Care Med. 2010 Apr;38(4 Suppl):e43-51. doi: 10.1097/CCM.0b013e3181c85229. Review.

PMID:
19935416
19.

Influenza viruses resistant to neuraminidase inhibitors.

Nitsch-Osuch A, Brydak LB.

Acta Biochim Pol. 2014;61(3):505-8. Epub 2014 Sep 8. Review.

20.

[Influenza A, pregnancy and neuraminidase inhibitors].

Montané E, Lecumberri J, Pedro-Botet ML.

Med Clin (Barc). 2011 May 28;136(15):688-93. doi: 10.1016/j.medcli.2010.02.006. Epub 2010 Apr 22. Review. Spanish.

PMID:
20416906

Supplemental Content

Support Center